TrovaGene (TROV) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $9 and the lowest price target forecast is $4. The average forecast of all the analysts is $7 and the expected standard deviation is $2.65.
TrovaGene (TROV) : 2 brokerage houses believe that TrovaGene (TROV) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on TrovaGene (TROV). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 3 Wall Street Analysts endorse the stock as a Buy with a rating of 1.67.
Also, Cantor Fitzgerald upgrades its view on TrovaGene (NASDAQ:TROV) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Earlier, the shares had a rating of Hold. The rating by the firm was issued on August 8, 2016.
TrovaGene (NASDAQ:TROV): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.91 and $4.83 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.98. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.96, notching a gain of 1.02% for the day. The total traded volume was 120,662 . The stock had closed at $4.91 on the previous day.
Trovagene, Inc. is a development-stage molecular diagnostic company that focuses on the development and commercialization of urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. The Companys primary internal focus is to leverage its urine-based molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. Its cell-free BRAF test confirms the presence of a BRAF V600E mutation in urine DNA at levels of greater than or equal to 0.03% in comparison to the wild-type BRAF genes. Its KRAS mutation assay detects and monitors the seven commonly encountered mutations of the KRAS oncogene. Its urine-based Human Papilloma Virus (HPV) assay identifies women with high grade cervical intraepithelial neoplasia (CIN2/3).